Home > Insider Trading > Filing (0000885590-11-000082)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
885590	Valeant Pharmaceuticals International Inc.	VRX	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1536053	Bradley Howard Schiller	7150 Mississauga Road Mississauga A6 L5N 8M5	Evp And Cfo	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, No Par Value	Acquisiton	2011-12-01	21,500	$46.05	21,500	No	4	P	Direct
Common Stock, No Par Value	Acquisiton	2011-12-02	11,000	$46.26	32,500	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Shares, No Par Value	Non-Qualified Stock Options (right to purchase)	Acquisiton	2011-12-01	200,000	$46.21	200,000	$46.21
Common Shares, No Par Value	Restricted Share Units	Acquisiton	2011-12-01	90,000	$0.00	90,000	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
200,000	2015-12-01	2021-12-01	No	4	A	Direct
90,000			No	4	A	Direct

Footnotes

Represents the weighted average purchase price. Purchases were made in the range of $45.85 to $46.47.
Represents the weighted average purchase price. Purchases were made in the range of $46.10 to $46.325.
The options vest 25% per year for 4 years starting from the date of grant with the first vest date falling on the first anniversary of the grant, the second vest date falling on the second anniversary of the grant, the third vest date falling on the third anniversary of the grant and the fourth vest date falling on the fourth anniversary of the grant.
Each Restricted Share Unit ("RSUs") represents a contingent right to receive between zero and three common shares, no par value, of Valeant Pharmaceuticals International, Inc. ("Valeant"), subject to performance based vesting criteria. See note (5).
The performance based RSUs are eligible to vest on the achievement of TSR targets ranging from 15% to 45% over a base price of $42.695 on each of three measurement dates: 25% would vest on September 1, 2014, 50% on December 1, 2014 and 25% on March 1, 2014, with early vesting possible at higher TSR levels.